Clinical Trials Browser

OTHER × enfortumab vedotin × 90 days × Clear all

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Phase 2 Recruiting

Carcinoma, Adenoid Cystic

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

Advanced Bladder Cancer

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT07221942 2026-02-19

IMPROEV

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT06724159 2026-02-17

SOGUG-PRINCIS

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04754191 2026-02-12

ENCORE

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Phase 2 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

Phase 2 Recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04878029 2026-01-23

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell

NCT07139977 2026-01-20

EV-4-EC

Phase 2 Not yet recruiting

Endometrial Neoplasms